secwatch.observer — SEC 8-K summary
======================================

Issuer:     Olema Pharmaceuticals, Inc. (OLMA)
CIK:        0001750284
Form:       8-K
Filed at:   2026-05-26T11:05:16+00:00
Accession:  0001193125-26-237832
Event type: other_material
Sentiment:  positive
Materiality: 0.55
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Olema partners with Bayer for OP-3136 + darolutamide Phase 1b/2 in mCRPC; 36 patients, H2 2026 start
--------------------------------------------------------------------------------

- Olema and Bayer will evaluate OP-3136 (KAT6 inhibitor) combined with darolutamide in ~36 mCRPC patients.
- Phase 1b/2 study expected to initiate in second half of 2026; Bayer supplies darolutamide.
- Olema retains full global commercial and marketing rights to OP-3136; clinical data and inventions jointly owned.
- First clinical collaboration for OP-3136; builds on ongoing Phase 1/2 monotherapy and combination studies.
- Olema to present initial Phase 1 OP-3136 monotherapy data at ASCO on May 30, 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1750284/000119312526237832/0001193125-26-237832-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1750284/000119312526237832/olma-20260526.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-237832

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer